Glenmark Pharmaceuticals is currently trading at Rs. 438.10, up by 0.75 points or 0.17% from its previous closing of Rs. 437.35 on the BSE.
The scrip opened at Rs. 440.00 and has touched a high and low of Rs. 444.80 and Rs. 435.00 respectively. So far 868271 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 449.75 on 31-Aug-2012 and a 52 week low of Rs. 265.00 on 21-Dec-2011.
Last one week high and low of the scrip stood at Rs. 444.80 and Rs. 393.45 respectively. The current market cap of the company is Rs. 11910.53 crore.
The promoters holding in the company stood at 48.33% while Institutions and Non-Institutions held 39.85% and 11.82% respectively.
Glenmark Generics’ United States subsidiary, Glenmark Generics Inc, USA (GGI), has settled its litigation between Glenmark and Janseen Pharmaceuticals Inc (Janseen) over patent actions concerning Norgestimate and Ethinyl Estradiol Tablets USP, 0.18/0.25 mg, 0.215/0.025 mg and 0.25/0.025 mg tablets, the generic versions of Janssen Ortho Tricyclen LO tablets.
Under the settlement agreements, the company will be able to market and distribute Norgestimate and Ethinyl Estradiol USP, 0.18/0.25 mg, 0.215/0.025 mg and 0.25/0.025 mg tablets under a royalty bearing license from Janssen on December 1 2015, or earlier under certain circumstance.
Janseen currently markets its products as Ortho Tricyclen LO in the United States, indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Total US sales as reported by IMS Health for the 12 months period ending June 2012 were approximately $ 397 million.
Glenmark Generics (GGL) is a subsidiary of Glenmark Pharmaceuticals and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence. It primarily sells FDF products in the United States and the European Union, as well as its oncology FDF products in South America.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1826.25 |
| Dr. Reddys Lab | 1368.95 |
| Cipla | 1489.05 |
| Lupin | 2252.60 |
| Zydus Lifesciences | 1010.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
